US20200030273A1 - Method and composition for surgery preparedness and recovery - Google Patents

Method and composition for surgery preparedness and recovery Download PDF

Info

Publication number
US20200030273A1
US20200030273A1 US16/045,994 US201816045994A US2020030273A1 US 20200030273 A1 US20200030273 A1 US 20200030273A1 US 201816045994 A US201816045994 A US 201816045994A US 2020030273 A1 US2020030273 A1 US 2020030273A1
Authority
US
United States
Prior art keywords
composition
arginine
surgery
nitric oxide
citrulline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/045,994
Inventor
Simon Frederick Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US16/045,994 priority Critical patent/US20200030273A1/en
Publication of US20200030273A1 publication Critical patent/US20200030273A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain

Definitions

  • the present invention relates to compositions and a method to accelerate wound healing and reduce complications and accelerate recovery associated with a surgical procedure.
  • Wound healing is generally recognized to occur in three phases with different cell types performing different functions. These phases are generally divided into the inflammatory phase, followed by the proliferation phase and finally the remodeling phase.
  • the inflammatory phase occurs immediately after the wound is formed and can last up to 3 days.
  • the inflammatory phase starts by blood vessel contraction and blood clot formation.
  • This process is protective and stops bleeding, it can cause the tissue around the wound to become ischemic, causing an anaerobic cellular metabolism leading to acidosis, decreased cellular glycogen and ATP levels that cause reduced cell membrane function, and vascular endothelial adhesions.
  • This leads to inflammation and complications associated with inflammation, such as pain and swelling.
  • further damage to the ischemic tissue can be caused by free radical influx, neutrophils, and the depletion of nitric oxide. This is known as an ischemia-reperfusion injury and they can impair wound healing.
  • the proliferation phase occurs after the inflammatory phase and can last up to 30 days. During this phase, tissue is regenerated and blood vessels are rebuilt (angiogenesis), collagen is formed and epithelialization occurs.
  • Nitric oxide is a mediator in reparative processes of angiogenesis, epithelialization and collagen formation. Nitric oxide also plays a critical role in the body as a mediator of vasodilation and the immune system. Depletion of nitric oxide in the inflammatory phase causes vasoconstriction, leading to the aggravation of interstitial edema, accumulation of toxins, and the production of pro-inflammatory mediators
  • L-arginine is the bodies precursor to nitric oxide. Surgical trauma and pre-surgical fasting can impair l-arginine production. Orally administered l-arginine is poorly absorbed by the body due to the first metabolism by arginase and further metabolism of systemic l-arginine by the liver. This results in a negligible increase in endothelial nitric oxide production when exogenous l-arginine is administered orally.
  • L-arginine can be made by the body from l-citrulline. Exogenous administration of l-citrulline results in slow conversions to l-arginine due to poor extraction from systemic circulation and inefficient metabolism in the liver and digestive system.
  • U.S. Pat. No. 5,576,351A describes the oral administration of l-arginine and ornithine as an immunostimulator. Due to the poor bioavailability mentioned, and ornithine's lack of involvement in nitric oxide synthesis, this invention does not notably increase nitric oxide production and stimulates the immune system by inducing the secretion of pancreatic and pituitary hormones.
  • L-glutamine is an abundant amino acid used in protein synthesis. Exogenous l-glutamine supplementation has been reported to enhance immune response.
  • Proteolytic enzymes such as bromelain—selectively catalyze the breakdown of proteins and have been shown to reduce ecchymosis and edemas.
  • Tissue damage, drugs and anesthetic gases used in surgery cause large amounts of physical stress on the body. Patients are left with bruising, pain, swelling and inflammation that causes pain and discomfort for up to months after the procedure, delaying their recovery and return to work and regular activities. Complications such as the formation of chronic wounds can put the patient's life at risk.
  • the present invention is directed to orally acceptable micronutrient compositions to enhance nitric oxide production in order to accelerate wound healing and reduce recovery time and complications associated with surgery.
  • compositions essential comprise of a unit dose of l-arginine and l-citrulline in relative mass ratios between about 0.3 and 3.0 (l-arginine/l-citrulline), for a total mass of no less than 1 g and no more than 20 g.
  • micronutrient compositions may further include one or more antioxidants, amino acids, proteolytic enzymes and/or hemolytic enzymes to address additional dietary and/or health concerns, and/or effects beneficial to wound healing.
  • the present invention is further directed to a method for administering the compositions in a timed manner to modulate the wound healing phases in order to reduce complications, accelerate wound healing, and accelerate the recovery time after surgery.
  • the method includes the administration of said micronutrient compositions at least 2 days before a surgical procedure and continued for at least 3 days thereafter.
  • the present invention relates to an orally administrable composition
  • an orally administrable composition comprising a combination of l-arginine and l-citrulline in specific ratios to enhance bioavailability and increase nitric oxide production in order to enhance wound healing and reduce complications associated with surgical trauma.
  • the invention also may contain one or more additional antioxidants and/or amino acids used in tissue production, and/or proteolytic and/or hemolytic enzymes.
  • the present invention is further directed to a method for the administration of said compositions for surgical preparedness and the modulation of the phases of wound healing in order to: reduce complications from surgery (including but not limited to complications due to inflammation, in particular ischemia-reperfusion injury, pain, swelling and bruising) accelerate wound healing, as well as accelerating the recovery period after surgery.
  • complications from surgery including but not limited to complications due to inflammation, in particular ischemia-reperfusion injury, pain, swelling and bruising
  • accelerate wound healing as well as accelerating the recovery period after surgery.
  • Nitric oxide is responsible for controlling blood vessel dilation and regulating blood flow. Nitric oxide also plays a critical role in the inflammatory and proliferation phases of wound healing. Specifically, nitric oxide is a mediator in the formation of new blood vessels (angiogenesis), wound healing (epithelization) and collagen formation. Depletion of nitric oxide in the inflammatory phase is partially responsible for ischemia-reperfusion injuries, which can delay healing and lead to the formation of chronic wounds.
  • L-arginine and l-citrulline are used by the body in the synthesis or nitric oxide, however oral administration of l-arginine or l-citrulline on their own results in negligible increases in endothelial nitric oxide production.
  • L-arginine get rapidly broken down in the digestive system by the enzyme arginase as part of the urea cycle. This converts l-arginine to ornithine and urea, resulting in no nitric oxide production.
  • L-citrulline can be converted by the body to l-arginine.
  • this process is slow and inefficient resulting in low levels of l-arginine and nitric oxide production at a given time.
  • L-citrulline can inhibit arginase activity allowing more efficient absorption of l-arginine. Excess l-citrulline can be converted to l-arginine for sustained and longer acting nitric oxide production.
  • the favoring of the nitric oxide pathway by the inhibition of arginase enables the invention to increase nitric oxide production at relatively low doses, avoiding negative side effects associated with high doses of the amino-acids which include gout, abdominal pain, acid-reflux and diarrhea.
  • Embodiments of the composition should contain a unit dose of at least 1 g total of l-arginine and l-citrulline in mass ratios between 0.3 and 3.0 (l-arginine/l-citrulline).
  • the unit dose should not contain in excess of about 20 g total of l-arginine and l-citrulline as undesirable side effects such as abdominal pain and diarrhea may occur.
  • a unit dose may contain additional antioxidants, amino acids, proteolytic and/or hemolytic enzymes. These can be used to address additional dietary and/or health concerns and/or be used to provide additional anti-inflammatory effects and/or effects beneficial to wound healing.
  • antioxidants examples include, but is not limited to: resveratrol, beta-carotene, lutein, quercetin, and vitamin C.
  • Examples of additional beneficial amino acids includes, but is not limited to: leucine, isoleucine, valine and glutamine.
  • proteolytic and hemolytic enzymes examples include, but is not limited to: bromelain and papain.
  • Examples of additional nutrients for a most preferred embodiment includes: vitamin C, l-glutamine, and bromelain.
  • Antioxidants scavenge inflammation causing free radicals which can be formed by tissue damage and oxidative stress.
  • Vitamin C has been shown to be a powerful and well tolerated antioxidant which theoretically could help reduce inflammation,
  • L-glutamine is an amino acid used in protein synthesis. Exogenous l-glutamine supplementation has been reported to improve immune response.
  • proteolytic enzymes help digest the proteins in food. Exogenous supplementation of proteolytic enzymes such as bromelain, can be absorbed internally and can help reduce ecchymosis and edemas.
  • a unit dose of a composition in accordance with a most preferred embodiment of the present invention includes: 1 g l-arginine, 1 g l-citrulline, 2 g l-glutamine, 500 mg vitamin C and 500 mg bromelain.
  • one-unit dose such as that described in [032] is taken twice daily, 3 days prior to the procedure, and one-unit dose of the composition is taken twice daily for 6 days after the procedure.
  • Other embodiments of the method may include the administration of the composition 2 to 5 days before surgery and be taken 3 days to up to 20 days after surgery.
  • composition of [032] may be individually packaged as a flavored powder in sealed foil for dilution in water and ingested orally.
  • the composition may be packaged as a bulk powder with an appropriately sized scoop to measure out the unit dose which can then be dissolved in water.
  • Another possible packaging option is to have the composition in a bottle or carton as an aqueous solution in either a unit dose or a bulk liquid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compositions and methods to increase nitric oxide production to: accelerate wound healing, reduce complications from surgery as well as accelerating the recovery period after surgery. The compositions comprise of l-arginine and l-citrulline in ratios and dosages which enable enhanced bioavailability. The method for using the composition for promoting surgery recovery and preparedness includes the step of administering the composition to a patient pre-procedure as well as post-procedure in accordance with a prescribed protocol. The compositions may be customized to include one or more additional agents that are effective for promoting nutritional health and/or treating a particular medical problem.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This patent claims the benefit of U.S. Provisional Application No. 62/539,748 filed Aug. 1, 2017.
    • BACKGROUND (i) FIELD OF THE INVENTION
  • The present invention relates to compositions and a method to accelerate wound healing and reduce complications and accelerate recovery associated with a surgical procedure.
    • (ii) BACKGROUND
  • Wound healing is generally recognized to occur in three phases with different cell types performing different functions. These phases are generally divided into the inflammatory phase, followed by the proliferation phase and finally the remodeling phase.
  • The inflammatory phase occurs immediately after the wound is formed and can last up to 3 days. The inflammatory phase starts by blood vessel contraction and blood clot formation. Although this process is protective and stops bleeding, it can cause the tissue around the wound to become ischemic, causing an anaerobic cellular metabolism leading to acidosis, decreased cellular glycogen and ATP levels that cause reduced cell membrane function, and vascular endothelial adhesions. This leads to inflammation and complications associated with inflammation, such as pain and swelling. After bleeding stops and blood flow is restored, further damage to the ischemic tissue can be caused by free radical influx, neutrophils, and the depletion of nitric oxide. This is known as an ischemia-reperfusion injury and they can impair wound healing.
  • The proliferation phase occurs after the inflammatory phase and can last up to 30 days. During this phase, tissue is regenerated and blood vessels are rebuilt (angiogenesis), collagen is formed and epithelialization occurs.
  • Nitric oxide is a mediator in reparative processes of angiogenesis, epithelialization and collagen formation. Nitric oxide also plays a critical role in the body as a mediator of vasodilation and the immune system. Depletion of nitric oxide in the inflammatory phase causes vasoconstriction, leading to the aggravation of interstitial edema, accumulation of toxins, and the production of pro-inflammatory mediators
  • L-arginine is the bodies precursor to nitric oxide. Surgical trauma and pre-surgical fasting can impair l-arginine production. Orally administered l-arginine is poorly absorbed by the body due to the first metabolism by arginase and further metabolism of systemic l-arginine by the liver. This results in a negligible increase in endothelial nitric oxide production when exogenous l-arginine is administered orally.
  • L-arginine can be made by the body from l-citrulline. Exogenous administration of l-citrulline results in slow conversions to l-arginine due to poor extraction from systemic circulation and inefficient metabolism in the liver and digestive system.
  • U.S. Pat. No. 5,576,351A describes the oral administration of l-arginine and ornithine as an immunostimulator. Due to the poor bioavailability mentioned, and ornithine's lack of involvement in nitric oxide synthesis, this invention does not notably increase nitric oxide production and stimulates the immune system by inducing the secretion of pancreatic and pituitary hormones.
  • L-glutamine is an abundant amino acid used in protein synthesis. Exogenous l-glutamine supplementation has been reported to enhance immune response.
  • Proteolytic enzymes—such as bromelain—selectively catalyze the breakdown of proteins and have been shown to reduce ecchymosis and edemas.
  • Tissue damage, drugs and anesthetic gases used in surgery cause large amounts of physical stress on the body. Patients are left with bruising, pain, swelling and inflammation that causes pain and discomfort for up to months after the procedure, delaying their recovery and return to work and regular activities. Complications such as the formation of chronic wounds can put the patient's life at risk.
    • SUMMARY
  • The present invention is directed to orally acceptable micronutrient compositions to enhance nitric oxide production in order to accelerate wound healing and reduce recovery time and complications associated with surgery.
  • The compositions essential comprise of a unit dose of l-arginine and l-citrulline in relative mass ratios between about 0.3 and 3.0 (l-arginine/l-citrulline), for a total mass of no less than 1 g and no more than 20 g.
  • The micronutrient compositions may further include one or more antioxidants, amino acids, proteolytic enzymes and/or hemolytic enzymes to address additional dietary and/or health concerns, and/or effects beneficial to wound healing.
  • The present invention is further directed to a method for administering the compositions in a timed manner to modulate the wound healing phases in order to reduce complications, accelerate wound healing, and accelerate the recovery time after surgery. The method includes the administration of said micronutrient compositions at least 2 days before a surgical procedure and continued for at least 3 days thereafter.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to an orally administrable composition comprising a combination of l-arginine and l-citrulline in specific ratios to enhance bioavailability and increase nitric oxide production in order to enhance wound healing and reduce complications associated with surgical trauma. The invention also may contain one or more additional antioxidants and/or amino acids used in tissue production, and/or proteolytic and/or hemolytic enzymes.
  • The present invention is further directed to a method for the administration of said compositions for surgical preparedness and the modulation of the phases of wound healing in order to: reduce complications from surgery (including but not limited to complications due to inflammation, in particular ischemia-reperfusion injury, pain, swelling and bruising) accelerate wound healing, as well as accelerating the recovery period after surgery.
  • Nitric oxide is responsible for controlling blood vessel dilation and regulating blood flow. Nitric oxide also plays a critical role in the inflammatory and proliferation phases of wound healing. Specifically, nitric oxide is a mediator in the formation of new blood vessels (angiogenesis), wound healing (epithelization) and collagen formation. Depletion of nitric oxide in the inflammatory phase is partially responsible for ischemia-reperfusion injuries, which can delay healing and lead to the formation of chronic wounds.
  • L-arginine and l-citrulline are used by the body in the synthesis or nitric oxide, however oral administration of l-arginine or l-citrulline on their own results in negligible increases in endothelial nitric oxide production.
  • L-arginine get rapidly broken down in the digestive system by the enzyme arginase as part of the urea cycle. This converts l-arginine to ornithine and urea, resulting in no nitric oxide production.
  • L-citrulline can be converted by the body to l-arginine. However, this process is slow and inefficient resulting in low levels of l-arginine and nitric oxide production at a given time.
  • The present inventions composition of orally administered l-arginine and l-citrulline taken together, in specific ratio ranges and dosages, inhibits the urea pathway and favors the production of nitric oxide. L-citrulline can inhibit arginase activity allowing more efficient absorption of l-arginine. Excess l-citrulline can be converted to l-arginine for sustained and longer acting nitric oxide production. The favoring of the nitric oxide pathway by the inhibition of arginase enables the invention to increase nitric oxide production at relatively low doses, avoiding negative side effects associated with high doses of the amino-acids which include gout, abdominal pain, acid-reflux and diarrhea.
  • Embodiments of the composition should contain a unit dose of at least 1 g total of l-arginine and l-citrulline in mass ratios between 0.3 and 3.0 (l-arginine/l-citrulline). The unit dose should not contain in excess of about 20 g total of l-arginine and l-citrulline as undesirable side effects such as abdominal pain and diarrhea may occur. A unit dose may contain additional antioxidants, amino acids, proteolytic and/or hemolytic enzymes. These can be used to address additional dietary and/or health concerns and/or be used to provide additional anti-inflammatory effects and/or effects beneficial to wound healing.
  • Examples of additional antioxidants includes, but is not limited to: resveratrol, beta-carotene, lutein, quercetin, and vitamin C.
  • Examples of additional beneficial amino acids includes, but is not limited to: leucine, isoleucine, valine and glutamine.
  • Examples of additional proteolytic and hemolytic enzymes includes, but is not limited to: bromelain and papain.
  • Examples of additional nutrients for a most preferred embodiment includes: vitamin C, l-glutamine, and bromelain.
  • Antioxidants scavenge inflammation causing free radicals which can be formed by tissue damage and oxidative stress. Vitamin C has been shown to be a powerful and well tolerated antioxidant which theoretically could help reduce inflammation,
  • L-glutamine is an amino acid used in protein synthesis. Exogenous l-glutamine supplementation has been reported to improve immune response.
  • Proteolytic enzymes (proteases) help digest the proteins in food. Exogenous supplementation of proteolytic enzymes such as bromelain, can be absorbed internally and can help reduce ecchymosis and edemas.
  • A unit dose of a composition in accordance with a most preferred embodiment of the present invention includes: 1 g l-arginine, 1 g l-citrulline, 2 g l-glutamine, 500 mg vitamin C and 500 mg bromelain.
  • In accordance with the most preferred method for surgical preparedness and recovery, one-unit dose such as that described in [032] is taken twice daily, 3 days prior to the procedure, and one-unit dose of the composition is taken twice daily for 6 days after the procedure. Other embodiments of the method may include the administration of the composition 2 to 5 days before surgery and be taken 3 days to up to 20 days after surgery.
  • In a preferred embodiment the composition of [032] may be individually packaged as a flavored powder in sealed foil for dilution in water and ingested orally.
  • In other embodiments of the invention, the composition may be packaged as a bulk powder with an appropriately sized scoop to measure out the unit dose which can then be dissolved in water. Another possible packaging option is to have the composition in a bottle or carton as an aqueous solution in either a unit dose or a bulk liquid.
  • It will be apparent to those skilled in the art that various other changes and modifications can be made without departing from the scope and spirit of the invention. The embodiments described do not limit the claims made to this invention and any modifications containing any or all features of the invention are intended to be covered in the appended claims.

Claims (3)

1. A micronutrient composition to enhance nitric oxide production administered in a unit dose wherein said unit dose comprises:
a. The amino-acids l-arginine and l-citrulline in mass ratios between about 0.3 and 3.0 (l-arginine/l-citrulline) with a combined total mass of between about 1 g and 20 g.
2. A composition of claim 1, wherein said unit dose further includes one or more antioxidant(s), amino acid(s) and/or proteolytic or hemolytic enzyme(s). This includes, but is not limited to: vitamin C, glutamine, and bromelain.
3. A method to reduce complications associated with a surgical procedure comprising the step of orally administering a unit dose of the composition of claims 1 and/or 2 to the patient beginning at least 2 days prior to a surgical procedure and at least 3 days after.
US16/045,994 2018-07-26 2018-07-26 Method and composition for surgery preparedness and recovery Abandoned US20200030273A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/045,994 US20200030273A1 (en) 2018-07-26 2018-07-26 Method and composition for surgery preparedness and recovery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/045,994 US20200030273A1 (en) 2018-07-26 2018-07-26 Method and composition for surgery preparedness and recovery

Publications (1)

Publication Number Publication Date
US20200030273A1 true US20200030273A1 (en) 2020-01-30

Family

ID=69177782

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/045,994 Abandoned US20200030273A1 (en) 2018-07-26 2018-07-26 Method and composition for surgery preparedness and recovery

Country Status (1)

Country Link
US (1) US20200030273A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210177025A1 (en) * 2018-09-24 2021-06-17 Tastes Natural, Llc Process for isolating taste-modifiers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210177025A1 (en) * 2018-09-24 2021-06-17 Tastes Natural, Llc Process for isolating taste-modifiers

Similar Documents

Publication Publication Date Title
Wild et al. Basics in nutrition and wound healing
Tengborn et al. Tranexamic acid–an old drug still going strong and making a revival
US4177261A (en) Pharmaceutical composition and method of stimulating blood circulation and wound healing
US20200030273A1 (en) Method and composition for surgery preparedness and recovery
JP2018150359A (en) Citrate-rich calcium-magnesium supplement and uses thereof
Bozzetti et al. Management of lymphatic fistulas by total parenteral nutrition
US20120020947A1 (en) Compositions and methods for increasing lean muscle mass after exercise
JP2008543902A (en) Methods and compositions for treating skin ulcers
US6413512B1 (en) Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
US5656588A (en) Wound healing formula
EP0730868A1 (en) Formulated medicines for treatment of oral inflammation, and processed foods to treat and prevent stomatitis
WO2003063780A3 (en) Therapeutic composition for treatment of cancer by arginine depletion
US6797729B1 (en) Therapeutic glutamine and N-actyl-cysteine composition
TWI403276B (en) Nutritional composition for wound healing
CN113645966A (en) Dosing regimen for orally absorbed highly soluble T4 thyroid hormone solution
US20100080856A1 (en) Method and composition for postoperative wound healing
CN1507860A (en) Complex prescription preparation of local application for promoting chronic wound healing
US20200323940A1 (en) Dietary supplements and use thereof on menses
BG4276U1 (en) Means for treatment of gynaecological adhesions and processes associated with ovarian aging
WO1999041361A1 (en) Protease-based dietary supplementation for decreasing recovery time from soft-tissue injury
CN106692957A (en) Freeze-drying technique of chymotrypsin aseptic freeze-dried powder
US11896611B1 (en) Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation
WO2021187942A1 (en) Use of cyclo-hispro (chp) for lowering blood pressure
US20230117618A1 (en) Oral Supplement to Trigger Repair Of Organs
CN101745095A (en) Composition of reduced glutathione and sodium carbonate or sodium bicarbonate

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION